Table of Contents Author Guidelines Submit a Manuscript
HPB Surgery
Volume 2010, Article ID 309780, 8 pages
http://dx.doi.org/10.1155/2010/309780
Clinical Study

Cyberknife Stereotactic Body Radiation Therapy for Nonresectable Tumors of the Liver: Preliminary Results

1Departments of Surgery, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
2Departments of Radiation Oncology, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
3Departments of Medicine, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA

Received 24 November 2009; Revised 12 April 2010; Accepted 24 May 2010

Academic Editor: Olivier Farges

Copyright © 2010 K. Goyal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and secondary malignancies of the liver. We report on our updated experience with SBRT in patients with non-resectable tumors of the liver. Methods. Our first 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC ( 𝑛 = 6 ), IHC ( 𝑛 = 3 ), and LM ( 𝑛 = 8 ) are presented. Mean radiation dose was 34Gy delivered over 1–3 fractions. Results. Treated patients had a mean decrease in maximum pretreatment tumor diameter from 6 . 9 Β± 4 . 6  cm to 5 . 0 Β± 2 . 1  cm at three months after treatment ( 𝑃 < . 0 5 ). The mean total tumor volume reduction was 44% at six months ( 𝑃 < . 0 5 ). 82% of all patients (14/17) achieved local control with a median follow-up of 8 months. 100% of patients with HCC ( 𝑛 = 6 ) achieved local control. Patients with surgically placed fiducial markers had no complications related to marker placement. Conclusion. Our preliminary results showed that SBRT is a safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events. Further studies are needed to define its role in the management of these malignancies.